Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[The increasing problem of the nonmedical use of medical cannabis].

Der Nervenarzt·2026

Same author

From controversy to clinical evidence: the evolving role of cannabis in pain therapy.

European archives of psychiatry and clinical neuroscience·2026

Same author

[The diamorphine treatment of opioid addicts-On the amendment of the indication criteria according to the narcotics prescription regulation].

Der Nervenarzt·2025

Same author

Stimulant and hallucinogenic novel psychoactive substances; an update.

Expert review of clinical pharmacology·2023

Same author

[Joint crisis plans in mental health hospitals-Real practice in an association of psychiatric hospitals].

Der Nervenarzt·2022

Same author

A Pan-European Review of Good Practices in Early Intervention Safeguarding Practice with Children, Young People and Families: Evidence Gathering to Inform a Multi-disciplinary Training Programme (the ERICA Project) in Preventing Child Abuse and Neglect in Seven European Countries.

International journal on child maltreatment : research, policy and practice·2022

Search research articles

Related Experiment Video

Updated: May 31, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

[Cannabis hyperemesis syndrome].

U Bonnet¹, D-I Chang, N Scherbaum

¹Klinik für Psychiatrie und Psychotherapie, LVR-Klinikum Essen, Universität Duisburg/Essen. udo.bonnet@uni-due.de

Fortschritte Der Neurologie-Psychiatrie

|June 22, 2011

Summary

This summary is machine-generated.

Cannabis use can trigger cyclical hyperemesis syndrome in dependent individuals. Abstinence and hot showers provided relief, suggesting hypothalamic cannabinoid system involvement.

More Related Videos

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Related Experiment Videos

Last Updated: May 31, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Area of Science:

Neuroscience
Endocrinology
Toxicology

Background:

Cannabis use disorder is prevalent in young adults.
Cyclical hyperemesis syndrome (CHS) is a rare condition characterized by recurrent nausea and vomiting.
The endocannabinoid system plays a role in various physiological processes, including appetite and nausea regulation.

Observation:

A young, otherwise healthy female adult with cannabis dependence developed cyclical hyperemesis.
Hyperemesis symptoms correlated with increased cannabis inhalation.
Symptomatic relief was observed with hot showers/baths, a known intervention for CHS.
The patient experienced complete remission of hyperemesis after several days of abstinence in an inpatient setting.

Findings:

Cannabis-induced cyclical hyperemesis is a potential diagnosis in cannabis-dependent individuals.
Thermosensitivity (improvement with hot showers) and a disturbed thyroid axis suggest involvement of the hypothalamic cannabinoid system.
Controlled cannabis abstinence led to sustained remission of symptoms for 4 months.

Implications:

This case highlights a potential adverse effect of chronic cannabis use.
The findings suggest the hypothalamic cannabinoid system is implicated in cannabis-induced hyperemesis.
Further research is warranted to understand the mechanisms and prevalence of this condition.